Turps, not that long a shot….
There’s been a notable shift by pharma in the past few years towards licensing earlier-stage assets. In 2017, pre-clinical and Phase 1 assets accounted for just under 60% of total pharma licensing deals.
https://resultshealthcare.com/insight/licensing-cornerstone-biotech-value-creation/
https://blog.lifesciencenation.com/...als-global-pharmas-looking-earlier-than-ever/
Ann: FDA meeting provides guidance for TPM/Oxymorphone patch, page-30
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $6 | 1.963K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 51 | 93002619 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 60312650 | 22 |
View Market Depth
| Last trade - 09.59am 23/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |